Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

Positive top-line data from phase II and III studies of lorundrostat for treating uncontrolled or resistant hypertension ...

RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has scheduled a conference call and webinar on Monday, March 10, ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

Researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas -- adrenal gland tumors that drive high blood pressure. Using cutting-edge analysis techniques, they ...